View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
September 6, 2017

Sanofi and Axxam start new CNS research collaboration

French pharmaceutical company Sanofi and Italian biotech firm Axxam have entered a new research collaboration in the field of neurodegenerative disorders.

By Lopamudra Roy

French pharmaceutical company Sanofi and Italian biotech firm Axxam have entered a new research collaboration in the field of neurodegenerative disorders.

The partnership will focus on further optimising a number of lead series of small molecules targeted against a wide range of central nervous system (CNS) disorders.

The current collaboration will help validate Axxam's platform to produce high-quality leads for small molecule drug discovery.

Through a high throughput screen (HTS) of the Axxam small molecule screening library, a range of tractable hit series of small molecules were generated under a programme initiated at Axxam.

Subsequent multi-parameter optimisation recognised potent and selective molecules with high CNS exposures and demonstrated effective results in disease-relevant pharmacology models.

"We are excited to open this latest chapter of our interactions with Sanofi."

After completing an initial in-house evaluation phase, the two companies will continue the programme under a joint research agreement, with the work on the project slated to be carried out at their research facilities.

If successful, Sanofi will have an option to enter a subsequent licensing agreement based on the research.

Axxam discovery research director Dr Russell Thomas said: “We are excited to open this latest chapter of our interactions with Sanofi.

“During the initial evaluation of our compounds in their laboratories we were impressed by the deep understanding of the target and its potential in addressing a broad range of neurodegenerative disorders with significant unmet medical needs.”

A partial funding of Axxam's prior work on the current programme is provided by the Alzheimer's Drug Discovery Foundation.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology